ABUS vs LDOS · P/E 5.4, rev $6.2M vs P/E 16, rev $16.66B
Arbutus Biopharma Corp (ABUS) versus Leidos Holdings Inc (LDOS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Leidos Holdings Inc (LDOS) is a information technology services company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LDOS revenue for 2025-01-03 was $16.66B. Net income was $1.25B. Revenue was up 7.9% from 2023-12-29 to 2025-01-03. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
Not investment advice. Open the ABUS and LDOS stock pages for the full models.
Not investment advice.